[1]Patent:WO2011/119457,2011,A1.Locationinpatent:Page/Pagecolumn3
[2]TetrahedronLetters,2016,vol.57,p.2601-2603
[3]Patent:WO2013/39854,2013,A1.Locationinpatent:Page/Pagecolumn32;33
[4]Patent:WO2014/62454,2014,A1.Locationinpatent:Page/Pagecolumn36
[1]Patent:WO2013/39854,2013,A1
[2]Patent:WO2014/62454,2014,A1
[3]TetrahedronLetters,2016,vol.57,p.2601-2603
[4]TetrahedronLetters,2016,vol.57,p.2601-2603
[1]Patent:WO2013/39854,2013,A1
[2]Patent:WO2014/62454,2014,A1
[3]TetrahedronLetters,2016,vol.57,p.2601-2603
[4]TetrahedronLetters,2016,vol.57,p.2601-2603
[1]Patent:WO2013/39854,2013,A1
[2]Patent:WO2014/62454,2014,A1
[3]TetrahedronLetters,2016,vol.57,p.2601-2603
[4]TetrahedronLetters,2016,vol.57,p.2601-2603
[1]Patent:WO2013/39854,2013,A1
[2]Patent:WO2014/62454,2014,A1
[3]TetrahedronLetters,2016,vol.57,p.2601-2603
[4]TetrahedronLetters,2016,vol.57,p.2601-2603
Title: Cellular impedance assays for predictive preclinical drug screening of kinase inhibitor cardiovascular toxicity.
Journal: Toxicological sciences : an official journal of the Society of Toxicology 20131001
Title: Effects of selective checkpoint kinase 1 inhibition on cytarabine cytotoxicity in acute myelogenous leukemia cells in vitro.
Journal: Clinical cancer research : an official journal of the American Association for Cancer Research 20121001
Title: Decreased translation of p21waf1 mRNA causes attenuated p53 signaling in some p53 wild-type tumors.
Journal: Cell cycle (Georgetown, Tex.) 20120501
Title: Preclinical development of the novel Chk1 inhibitor SCH900776 in combination with DNA-damaging agents and antimetabolites.
Journal: Molecular cancer therapeutics 20120201
Title: Targeting the replication checkpoint using SCH 900776, a potent and functionally selective CHK1 inhibitor identified via high content screening.
Journal: Molecular cancer therapeutics 20110401
Title: Montano R, et al. Preclinical development of the novel Chk1 inhibitor SCH900776 in combination with DNA-damaging agents and antimetabolites. Mol Cancer Ther. 2012 Feb;11(2):427-38.
Title: Guzi TJ, et al. Targeting the replication checkpoint using SCH 900776, a potent and functionally selective CHK1 inhibitor identified via high content screening. Mol Cancer Ther. 2011 Apr;10(4):591-602.
